- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Muscle Hypertrophy.
Displaying page 1 of 2.
EudraCT Number: 2014-002083-33 | Sponsor Protocol Number: 2012CV15 | Start Date*: 2014-07-22 | ||||||||||||||||
Sponsor Name:University of Dundee/NHS Tayside | ||||||||||||||||||
Full Title: Does Allopurinol regress Left Ventricular Hypertrophy in Patients with Treated Essential Hypertension? | ||||||||||||||||||
Medical condition: Left ventricular hypertrophy in hypertension | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001375-11 | Sponsor Protocol Number: not applicable | Start Date*: 2007-05-16 |
Sponsor Name: | ||
Full Title: Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease Long-term follow-up of patients receiving commercially available Myozyme | ||
Medical condition: Pompe disease (glycogen storage disease type II) is a genetic, lysosomal storage disorder with a frequency of 1 in 40.000 newborns. The disease is caused by deficiency of alpha-glucosidase, a lysos... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002305-38 | Sponsor Protocol Number: 2013CV11 | Start Date*: 2015-01-21 | ||||||||||||||||||||||||||
Sponsor Name:University of Dundee/ NHS Tayside | ||||||||||||||||||||||||||||
Full Title: Does allopurinol reduce right ventricular mass in lung disease associated pulmonary hypertension? | ||||||||||||||||||||||||||||
Medical condition: right ventricular hypertrophy associated with COPD or Interstitial Lung Disease and pulmonary hypertension | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000715-33 | Sponsor Protocol Number: 2015DM07 | Start Date*: 2016-12-19 | ||||||||||||||||
Sponsor Name:University of Dundee & NHS Tayside | ||||||||||||||||||
Full Title: Does Dapaglifozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? | ||||||||||||||||||
Medical condition: Type 2 diabetes and left ventricular hypertrophy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001436-22 | Sponsor Protocol Number: 2012CV07 | Start Date*: 2013-08-06 |
Sponsor Name:University of Dundee/NHS Tayside | ||
Full Title: Does ALlopurinol regress lefT ventricular hypertrophy in End stage REnal Disease: The ALTERED study | ||
Medical condition: Renal failure and left ventricular hypertrophy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000222-35 | Sponsor Protocol Number: 2017-000222-35 | Start Date*: 2017-07-21 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients – a randomized controlled trial | ||
Medical condition: Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006664-29 | Sponsor Protocol Number: cro955 | Start Date*: 2008-02-26 | |||||||||||
Sponsor Name:Imperial College | |||||||||||||
Full Title: The effect of inhaled corticosteroids (ICS) on airway smooth muscle in asthma | |||||||||||||
Medical condition: Asthma is a disease characterised by reversible airways obstruction, bronchial hyper-responsiveness (BHR), and chronic inflammation of the bronchial mucosal lining. Structural changes in the airwa... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003392-10 | Sponsor Protocol Number: CMEK162Y2201 | Start Date*: 2012-01-23 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy. | ||||||||||||||||||
Medical condition: Noonan syndrome hypertrophic cardiomyopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000686-40 | Sponsor Protocol Number: pulsar | Start Date*: 2023-05-04 | |||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | |||||||||||||
Full Title: Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis | |||||||||||||
Medical condition: cardiac amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002585-33 | Sponsor Protocol Number: PETAL | Start Date*: 2023-01-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) | ||||||||||||||||||
Medical condition: cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020611-36 | Sponsor Protocol Number: AGLU07310 | Start Date*: 2011-10-12 | |||||||||||
Sponsor Name:Genzyme Europe B.V. | |||||||||||||
Full Title: A Phase 4 Prospective Exploratory Muscle Biopsy, Biomarker, and Imaging Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa | |||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004039-64 | Sponsor Protocol Number: MYK-461-007 | Start Date*: 2019-11-14 | |||||||||||
Sponsor Name:MyoKardia, Inc. | |||||||||||||
Full Title: A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE) | |||||||||||||
Medical condition: Hypertrophic Cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) DE (Restarted) DK (Trial now transitioned) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001191-19 | Sponsor Protocol Number: 2011-400 | Start Date*: 2011-10-26 | |||||||||||
Sponsor Name:Hjertemedicinsk klinik B, 2142, Rigshospitalet | |||||||||||||
Full Title: Cardiac effects of inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy. | |||||||||||||
Medical condition: Hypertrophic cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002530-23 | Sponsor Protocol Number: MYK-461-005 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:MyoKardia, Inc. | |||||||||||||
Full Title: A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy | |||||||||||||
Medical condition: Hypertrophic Cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) PT (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed) PL (Completed) DK (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003307-16 | Sponsor Protocol Number: OMT28-C0203 | Start Date*: 2023-04-18 | ||||||||||||||||
Sponsor Name:OMEICOS Therapeutics GmbH | ||||||||||||||||||
Full Title: A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD patients with myopathy and/or cardiomyopathy and inflammation (PMD-OPTION) | ||||||||||||||||||
Medical condition: Primary Mitochondrial Disease (PMD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001577-13 | Sponsor Protocol Number: CC-HCM-01 | Start Date*: 2014-07-15 | |||||||||||
Sponsor Name:Manchester University NHS Foundation Trust | |||||||||||||
Full Title: Copper Chelation in Hypertrophic Cardiomyopathy: Open-label pilot study of Trientine in patients with hypertrophic cardiomyopathy | |||||||||||||
Medical condition: Hypertrophic Cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002785-12 | Sponsor Protocol Number: CY6021 | Start Date*: 2020-05-25 | |||||||||||
Sponsor Name:Cytokinetics, Inc. | |||||||||||||
Full Title: A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomati... | |||||||||||||
Medical condition: obstructive hypertrophic cardiomyopathy (oHCM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000942-77 | Sponsor Protocol Number: EFC14028 | Start Date*: 2016-07-15 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase ... | |||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended) SE (Prematurely Ended) NL (Completed) ES (Ongoing) CZ (Completed) DE (Completed) BE (Completed) AT (Completed) PL (Completed) IT (Completed) PT (Completed) BG (Completed) HU (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003497-48 | Sponsor Protocol Number: EMPATHY | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial | |||||||||||||
Medical condition: acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021258-20 | Sponsor Protocol Number: EAST | Start Date*: 2011-06-15 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. (AFNET) | ||||||||||||||||||||||||||||||||||||||
Full Title: Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST) | ||||||||||||||||||||||||||||||||||||||
Medical condition: Atrial fibrillation, stroke, heart failure, myocardial infarction, cognitive dysfunction | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) DK (Completed) NL (Completed) CZ (Completed) BE (Completed) ES (Completed) PL (Completed) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.